Related Experiment Video
Updated: May 16, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir
Kristen M Marks1, Ira M Jacobson
1Division of Infectious Diseases, Weill Cornell Medical College, New York, NY, USA. markskr@med.cornell.edu
Abstract:
Boceprevir and telaprevir are peptidomimetic serine protease inhibitors that have been recently approved for the treatment of HCV chronic infection. The addition of these drugs to the prior standard of care, pegylated interferon and ribavirin, improves sustained virological response rates for treatment-naive and treatment-experienced patients and shortens the duration of treatment for over half of treatment-naive patients. This review describes the clinical data supporting the approval and use of telaprevir and boceprevir, the algorithm for the use of these drugs, their adverse effects, as well as their important drug-drug interactions.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Inhibitors of Viral Protein Synthesis
Retrovirus Life Cycles
Subviral Agents
Retroviruses

